熱門資訊> 正文

辉瑞RSV疫苗Abrysvo获得扩大适应症

2024-10-23 06:09

The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus.
Those conditions include obesity, diabetes, chronic obstructive pulmonary disease, heart failure, chronic kidney disease, and asthma.
Expanded approval was based on results of the phase 3 MONeT study, which examined the shot in adults at risk of RSV-associated disease due to certain chronic medical conditions.

More on Pfizer

Pfizer: Activists Clouding A Promising Picture
Pfizer: Investor Activism Is Not The Solution
Pfizer: A 6% Yielding Ultra SWAN Bargain With Upside Potential
Pfizer, Lilly relationships with telehealth platforms draw Sen. Durbin's attention
Pfizer has “significantly overpaid” for recent acquisitions: Starboard Value

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。